| Literature DB >> 31245375 |
Kari Murros1, Joonas Wasiljeff2, Elena Macías-Sánchez3, Damien Faivre3,4, Lauri Soinne1, Jussi Valtonen5, Marjatta Pohja1, Pekka Saari6, Lauri J Pesonen6, Johanna M Salminen2,6.
Abstract
Magnetic iron oxide nanoparticles, magnetite/maghemite, have been identified in human tissues, including the brain, meninges, heart, liver, and spleen. As these nanoparticles may play a role in the pathogenesis of neurodegenerative diseases, a pilot study explored the occurrence of these particles in the cervical (neck) skin of 10 patients with Parkinson's disease and 10 healthy controls. Magnetometry and transmission electron microscopy analyses revealed magnetite/maghemite nanoparticles in the skin samples of every study participant. Regarding magnetite/maghemite concentrations of the single-domain particles, no significant between-group difference was emerged. In low-temperature magnetic measurement, a magnetic anomaly at ~50 K was evident mainly in the dermal samples of the Parkinson group. This anomaly was larger than the effect related to the magnetic ordering of molecular oxygen. The temperature range of the anomaly, and the size-range of magnetite/maghemite, both refute the idea of magnetic ordering of any iron phase other than magnetite. We propose that the explanation for the finding is interaction between clusters of superparamagnetic and single-domain-sized nanoparticles. The source and significance of these particles remains speculative.Entities:
Keywords: Parkinson's disease; gut; human tissue; magnetite; nanoparticles; skin; superparamagnetic
Year: 2019 PMID: 31245375 PMCID: PMC6563768 DOI: 10.3389/fmed.2019.00123
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Demographic and clinical characteristics of patients and controls.
| Age in years, median (range) | 68.5 (55–74) | 70.5 (50–72) |
| Gender, male (%) | 50 | 50 |
| Years from PD diagnosis, median (range) | 8 (1–17) | - |
| Hoehn & Yahr stage, median (range) | 2.5 (1.5–4.0) | - |
| Years with PD patient, median (range) | 0 | 43 (1–50) |
| Body Mass Index, median (kg/m2) | 26.5 | 24.9 |
| Current smoking, prevalence (%) | 10 | 20 |
| Hypertension (medicated), prevalence (%) | 40 | 30 |
| Hyposmia by history, prevalence (%) | 80 | 0 |
Magnetic properties of dermal samples.
| 1D | 6.22 | 8.0 | 1640.0 | 20 | |
| 2D | 20.28 | 10.0 | 4408.7 | 118 | |
| 3D | 8.04 | 7.0 | 2428.1 | 41 | 121–123 |
| 6D | 51.23 | 4.0 | 27842.4 | ||
| 8D | 6.00 | 11.0 | 1219.2 | 54 | 120 |
| 10D | 20.37 | 4.0 | 12652.2 | 48 | 121 |
| 11D | 13.62 | 15.0 | 2028.0 | ||
| 12D | 30.54 | 8.0 | 8852.2 | 46 | 118 |
| 14D | 2.67 | 3.0 | 1733.0 | 42 | |
| 18D | 6.43 | 15.0 | 904.4 | 54 | |
| Mean | 6370.8 | ||||
| Average deviation | 6046.9 | ||||
| Median | 2228.1 | ||||
| 5D | 8.15 | 8.0 | 2108.4 | 121 | |
| 7D | 6.90 | 3.0 | 4713.3 | 117 | |
| 9D | 3.56 | 8.0 | 943.0 | ||
| 13D | 9.89 | 13.0 | 1653.8 | ||
| 15D | 5.77 | 2.0 | 5700.6 | 42 | 123 |
| 16D | 7.98 | 5.0 | 3854.1 | 125 | |
| 17D | 16.11 | 20.0 | 1759.9 | 115 | |
| 19D | 11.01 | 13.0 | 1855.4 | ||
| 20D | 1.89 | 2.0 | 1786.4 | ||
| 21D | 2.20 | 3.0 | 1913.0 | ||
| Mean | 2628.8 | ||||
| Average deviation | 1276.3 | ||||
| Median | 1884.2 | ||||
Tp, temperature for low temperature perturbation; Tv, Temperature for Verwey transition.
Magnetic properties of epidermal samples.
| 1E | 10.84 | 13.9 | 1695.3 | ||
| 2E | 2.49 | 6.5 | 832.8 | ||
| 3E | 17.08 | 11.0 | 3375.5 | ||
| 6E | 8.68 | 8.3 | 2273.2 | ||
| 8E | 21.31 | 7.5 | 6176.8 | ||
| 10E | 11.70 | 11.2 | 2272.8 | ||
| 11E | 18.25 | 25.7 | 1543.7 | ||
| 12E | 14.02 | 7.8 | 3907.5 | ||
| 14E | 4.33 | 4.2 | 2243.3 | ||
| 18E | 16.46 | 14.7 | 2434.2 | 122 | |
| Mean | 2675.5 | ||||
| Average deviation | 1086.7 | ||||
| Median | 2273.0 | ||||
| 5E | 31.66 | 9.7 | 7095.5 | ||
| 7E | 3.87 | 4.5 | 1869.6 | ||
| 9E | 6.18 | 6.1 | 2203.5 | ||
| 13E | 11.69 | 14.9 | 1705.6 | ||
| 15E | 5.66 | 2.6 | 4729.1 | ||
| 16E | 9.94 | 4.6 | 4697.5 | ||
| 17E | 16.11 | 18.7 | 1872.8 | 42 | 124 |
| 19E | 13.73 | 19.6 | 1522.8 | ||
| 20E | 16.44 | 6.2 | 5764.4 | ||
| 21E | 5.48 | 10.7 | 1113.8 | ||
| Mean | 3257.5 | ||||
| Average deviation | 1815.3 | ||||
| Median | 2038.2 | ||||
Tp, temperature for low temperature perturbation; Tv, Temperature for Verwey transition.
Figure 1Normalized saturation isothermal remanent magnetization (SIRM/SIRM0) as a function of demagnetizing AF field (semi-log) (A) for patient samples, (B) for control samples. Normalized acquisition of isothermal remanent magnetization (IRM/IRM1T) and normalized SIRM (SIRM/SIRM0) as a function of AF field for cervical skin samples of patients with PD (C,D) and for healthy controls (E,F). Wohlfarth's ratio (W) is defined from the intersection of these curves. MC, median coercivity; D, dermal; E, epidermal.
Figure 2Estimated magnetite concentration (micrograms per gram, μg/g) vs. median destructive field (MDF) of saturation isothermal remanent magnetization (SIRM) for dermal part of the cervical skin samples. Y-axis in logarithmic scale.
Figure 3Normalized induced magnetization as a function of temperature for ZFC (Mzfc/Mzfcmax) (A) patient samples and (B) control samples. Solid line–ca. 50 K anomaly or Verwey transition; dashed line–no low temperature features. For comparison, the magnetization values are normalized to maximum value of ZFC magnetization.
Figure 4(A) Normalized ZFC (Mzfc/Mzfcmax) and FC (Mfc/Mfcmax) curves for patient sample 18D exhibiting 50 K perturbation. (B) Induced magnetization as a function of field near the anomaly at 48 K and in 300 K after slope correction. Normalization of ZFC-FC as in Figure 3.
Figure 5High annular dark field (HAADF) image of particles extracted from human cervical skin with respective EEL spectra; A–C (Healthy control), D–F (PD patient). Iron L2.3-edge (B,E) and oxygen K-edge fine structure (C,F) confirm that particles are composed of magnetite.